Skip to the page

Data / Form D filings / Mekiri Bio, Inc.

Mekiri Bio, Inc.: Form D filing

Mekiri Bio, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2025. The latest, on October 16, 2025, reports $1 million sold of a $2 million offering to 1 investor.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
68 HARRISON AVENUE, SUITE 605, PMB 653323, Boston, MA, 02111
Phone
(617) 203-8458
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2025
Revenue range
Not Applicable
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
2088062

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Oct 16, 2025New notice$2,000,000$1,000,000$1,000,0001Aug 25, 2025sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Debbie LinExecutive Officer
Anita DiFazioExecutive Officer
Aaron DiAntonioDirector
Corey McCannDirector

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Oct 13, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what Mekiri Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.